C4 therapeutics appoints veteran biotechnology leader stephen fawell, ph.d. to board of directors

Watertown, mass., sept. 03, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its board of directors with the appointment of stephen (steve) fawell, ph.d. as a director. with this appointment, malcolm salter has decided to retire from the board of directors after nearly a decade of service.
CCCC Ratings Summary
CCCC Quant Ranking